Donald William Nicholson Form 3 Kymera Therapeutics / Donald William Nicholson ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Nicholson Donald William

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

200 ARSENAL YARDS BLVD. SUITE 230

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/20/2020

3. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,255	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	10/31/2028	Common Stock	16,439	1.31	D
Stock Option (Right to Buy)	(2)	05/22/2029	Common Stock	26,819	2.08	D
Stock Option (Right to Buy)	(3)	05/13/2030	Common Stock	21,944	5.33	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares underlying this stock option vested on November 21, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

2. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.

3. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 14, 2020, subject to the reporting person's continued employment through each vesting date.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Bruce N. Jacobs, as Attorney-in-Fact	08/20/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.